Observational studyMedicine2025
Quality of life after chemotherapy for advanced gastric cancer: S-1 vs. XELOX at 1 year after treatment.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Locally advanced gastric cancer requires radical gastrectomy, with postoperative adjuvant chemotherapy recommended for stage Ⅱ orⅢ gastric cancer. However, the impact of S-1 and XELOX on patients' quality of life (QoL) remains unclear. This study compared and analyzed the QoL of patients who received S-1 and XELOX as adjuvant chemotherapy after gastric cancer surgery. This study included 186 patients with gastric cancer who underwent curative resection at our hospital between January 2011 and May 2015. Of the patients, 130 and 56 received S-1 and XELOX, respectively. The QoL immediately after completion, 6 months after completion, and 1 year after completion of adjuvant chemotherapy was compared and analyzed. Changes over time were significantly different between the chemotherapy completion time point and 6 to 12 months post-completion in the European Organization for Research and Treatment of Cancer Core QoL Questionnaire domains of physical function (P = .004) and role function (P = .001). Regarding the European Organization for Research and Treatment of Cancer Gastric Cancer-Specific QoL Questionnaire, changes over time were significantly different in the reflux (P = .03) and taste (P = .02) domains. Patients receiving adjuvant chemotherapy after gastrectomy require intensive QoL management and intervention for up to 1 year.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.